Your browser is old and is not supported. Upgrade for better security.

Invest in Neurocarrus

New first-in-class sensory neuron specific pain drug treats pain without risk of addiction

$13,450

reserved of a $55,000 goal
INVESTMENT TERMS
$11.25M valuation cap Future Equity

Highlights

1
Drug candidate N-001 provides relief from severe pain in animals caused by inflammation or surgery.
2
N-001 cannot enter the brain and therefore cannot cause addiction.
3
N-001 provides pain relief equal to prescription drugs without side effects on muscles or balance.
4
N-001 is a targeted drug with a unique manufacturing process to discourage competitors.
5
There is a massive market for the treatment of severe pain both in the U.S. and abroad.
6
Neurocarrus has a strong track record of non-dilutive funding from federal and state government.
7
Founder has been working in the space for 25+ years trouble shooting commercial biologicals.
8
Patents issued on exclusively licensed technology in both the U.S. and select countries.

Our Team


Publications:

Animal efficacy and safety studies

Targeting, mechanism, and efficacy studies

Drug design and engineering studies

















Downloads

Overview